A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Study acronym: PRESTO
StatusRecruiting
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion moved earlier from Nov 5, 2027 to Aug 31, 2027
    • Eligibility criteria expanded, about 22 words
    • Secondary endpoints: details revised at 3 of 11 entries
    • Site details revised at 14 of 367 sites
  2. Study sites: 368 to 367v12
  3. Site details revised at 46 of 368 sitesv11
  4. Study sites: 366 to 368v10
  5. Enrollment reduced: 1160 → 987 participants
    • Trial sites expanded: 363 → 366 locations
    • Trial arms changed: 4 → 3
    • Study description expanded, about 7 words
    v9
Show 7 earlier versionsHide 7 earlier versions
  1. Study sites: 362 to 363v8
  2. Study sites: 356 to 362
    • Eligibility criteria expanded, about 5 words
    v7
  3. Study sites: 347 to 356v6
  4. Study sites: 345 to 347v5
  5. Study sites: 335 to 345v4
  6. Study sites: 293 to 335v3
  7. Study sites: 240 to 293v2
  1. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
AstraZeneca
734 trials monitored
See 61 trials at risk
COPD
1,127 trials monitored
See 38 trials at risk
This Phase IIb dose-ranging study will evaluate the efficacy and safety of 2 different doses of AZD6793 compared with placebo tablets in participants with moderate to very severe chronic obstructive pulmonary disease.
Trial Details
NCT Number NCT07082738
Lead Sponsor AstraZeneca
Conditions
(from sponsor)		 Chronic Obstructive Pulmonary Disease (COPD)
Related terms Pulmonary Disease, Chronic Obstructive
Enrollment 987 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov